Metro Rate Cards

Johnson and Johnson urged to pause COVID-19 vaccine use

The Johnson and Johnson COVID-19 vaccine


April 14, 2021 2 min read

2 min read


US health authorities are calling for a pause in the use of the Johnson & Johnson COVID-19 vaccine, after reports of extremely rare blood clotting cases, this is according to BBC News Service.

News reports show that the Food and Drug Administration (FDA) said it was acting 'out of an abundance of caution', because six cases of severe blood clotting had been detected in more than 6.8 million doses of the vaccine.
The recommendation follows similar rare cases in the AstraZeneca vaccine, which have prompted some curbs in its use.
BBC says the both FDA and the Centers for Disease Control and Prevention (CDC) were reviewing six reported US cases of a rare & severe type of blood clot in individuals after receiving the vaccine, but right now, these adverse events appear to be extremely rare.
“We are recommending a pause in the use of this vaccine out of an abundance of caution,” the FDA said.
This is said to be a measure to ensure that the health care provider community is aware of the potential for these adverse events.
A joint statement from the FDA and CDC clarified that the blood clotting was cerebral venous sinus thrombosis (CVST) which is said to need a different treatment than a usual one, adding that a common treatment - an anticoagulant drug called heparin 'may be dangerous', and an alternative is required.

 


Enjoy our daily newsletter from today

Access exclusive features and newsletters, along with previews of new media releases.


Metro News Digital

Get Your Online Newspaper

All six cases were in women aged between 18 and 48, with symptoms six to 13 days after vaccination.
The joint statement said: “People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.”
It added: “We are aware that thromboembolic events including those with thrombocytopenia have been reported with COVID-19 vaccines. At present, no clear causal relationship has been established between these rare events and the Janssen (J&J) COVID-19 vaccine.” LeNA

 

Share this story

[[message]]

Loading Question


Related Stories